Health Catalyst, Inc. (HCAT) - 10-K Summary
Business Context and Reporting Period
Company: Health Catalyst, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Health Catalyst provides a cloud-based data and analytics platform, software applications, and expertise to healthcare organizations. The company's "Solution" enables clients to manage data and derive insights for clinical, financial, and operational improvements. As of December 31, 2024, the company served 130 Platform Clients and over 900 App Clients.
Key Financial Metrics
| Metric | 2024 | 2023 | Change |
|---|---|---|---|
| Total Revenue | $306.6 million | $295.9 million | +4% |
| Net Loss | $(69.5) million | $(118.1) million | Improvement |
| Adjusted EBITDA | $26.1 million | $11.0 million | +137% |
| Gross Margin (GAAP) | 37% | 35% | +200 bps |
| Adjusted Gross Margin | 49% | 49% | Flat |
| Cash & Equivalents | $392.0 million | $317.7 million | +23% |
| Operating Cash Flow | $14.6 million | $(33.1) million | Positive Turnaround |
Debt & Liquidity:
- Convertible Notes: $230.0 million principal outstanding, maturing April 2025.
- Term Loan Facility: Entered July 2024; $125 million initial draw + $37.7 million delayed draw (Total drawn: $162.7 million). Interest rate: SOFR + 6.5%.
- Liquidity: The company reported $392.0 million in cash, cash equivalents, and short-term investments as of December 31, 2024.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 4% year-over-year, driven by new clients, contractual escalators, and revenue from recent acquisitions. Technology revenue grew 4% to $194.9 million; Professional Services grew 3% to $111.7 million.
- Profitability Improvement: Net loss narrowed significantly from $118.1 million in 2023 to $69.5 million in 2024. Adjusted EBITDA turned positive and more than doubled to $26.1 million.
- Cost Reduction: Operating expenses decreased by approximately $48 million year-over-year. Sales and marketing expenses dropped 19%, Research and Development dropped 20%, and General and Administrative expenses dropped 26%. These reductions were primarily due to lower stock-based compensation and the impact of the 2023 Restructuring Plan.
- Acquisitions: The company completed four acquisitions in 2024: Carevive, Lumeon, Intraprise, and Upfront (closed Jan 2025). These added to the client base and technology portfolio.
- Client Metrics: Platform Clients increased to 130 (from 109 in 2023). The updated Dollar-based Retention Rate for Technology and TEMS was 102% for 2024.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- Macroeconomic Environment: Management notes that while the healthcare end-market faced strain in prior years, operating margins improved in 2024. They anticipate this trend to continue as a tailwind in 2025.
- Platform Migration: The company is migrating clients from the legacy DOS platform to "Health Catalyst Ignite." This migration is expected to incur near-term costs that may negatively impact Technology Gross Margin, with completion anticipated by mid-2026.
- 2025 Expectations: Management expects net new Platform Clients to have an aggregated average total ARR and non-recurring revenue range of $300,000 to $700,000 in 2025.
Key Risks & Contingencies:
- Debt Maturity: The $230 million Convertible Senior Notes mature in April 2025. The company intends to settle these in cash but faces refinancing or conversion risks.
- Restructuring: A 2025 Restructuring Plan was authorized in January 2025, reducing the global workforce by approximately 4%, primarily in R&D and professional services.
- Regulatory & AI: Risks include evolving regulations regarding AI technologies, data privacy (HIPAA, GDPR), and potential FDA oversight of certain software features.
- Client Concentration: No single client represented more than 10% of revenue, but the top three clients accounted for 13.8% of 2024 revenue.
Investor Verification Checklist
- Debt Refinancing: Verify the company's plan and ability to repay or refinance the $230 million Convertible Notes maturing in April 2025.
- Ignite Migration Impact: Monitor the impact of the DOS-to-Ignite migration on Technology Gross Margins and client retention rates in upcoming quarters.
- Acquisition Integration: Assess the revenue contribution and integration costs of recent acquisitions (Carevive, Lumeon, Intraprise, Upfront).
- Restructuring Execution: Track the realization of cost savings from the 2025 Restructuring Plan and its effect on operating leverage.
- Stock-Based Compensation: Review the trajectory of stock-based compensation expenses, which decreased significantly in 2024 but remain a material non-cash expense.